Presented at the American Society of Hematology (ASH) 54th Annual Meeting; December 8-11, 2012; Atlanta, Georgia.
Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies
Article first published online: 19 SEP 2013
© 2013 American Cancer Society
Volume 119, Issue 24, pages 4308–4315, 15 December 2013
How to Cite
Burnette, B. L., Dispenzieri, A., Kumar, S., Harris, A. M., Sloan, J. A., Tilburt, J. C., Kyle, R. A. and Rajkumar, S. V. (2013), Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. Cancer, 119: 4308–4315. doi: 10.1002/cncr.28340
- Issue published online: 3 DEC 2013
- Article first published online: 19 SEP 2013
- Manuscript Accepted: 23 JUL 2013
- Manuscript Revised: 6 JUL 2013
- Manuscript Received: 10 JUN 2013
- multiple myeloma;
- autologous transplant;
- quality of life
Two randomized trials have demonstrated improved progression-free survival (PFS) with lenalidomide maintenance after autologous transplantation for multiple myeloma (MM). Overall survival (OS) results are conflicting, and quality-of-life (QOL) data are lacking. The authors conducted a systematic survey of patients with MM regarding what constitutes a meaningful benefit that would make burdens of maintenance treatments (toxicity and cost) acceptable.
A self-administered survey was mailed to 1159 consecutive, living patients who were evaluated at Mayo Clinic. The survey provided background information on the standard of care for MM and data on maintenance. Patients were asked to estimate the magnitude of OS benefit that would be acceptable for various degrees of toxicity and cost.
Of 1159 surveys sent, 886 patients (83.2%) responded, and 736 patients returned a completed survey (66% raw response rate). The most worrisome potential toxicity was identified as peripheral neuropathy by 27% of patients, cytopenias by 24%, deep vein thrombosis by 20%, fatigue by 15%, nausea by 8%, and diarrhea/constipation by 7%. If treatment was free, had no toxicity, and the OS benefit was ≤1 year, then 49% of patients indicated that they would choose maintenance; with moderate toxicity, this proportion decreased to 42%. Adding a treatment cost of $25 per month decreased the proportion that would choose maintenance to 39% of patients.
The current results indicated that willingness to receive maintenance treatment declined when actual benefits were provided in concrete numeric terms compared with a general statement of PFS benefit. The authors also observed that the magnitude of benefit required to consider maintenance was affected by cost and toxicity. Cancer 2013;119:4308–4315. © 2013 American Cancer Society.